Zelluna ASA (OSL:ZLNA)

kr 13.78 -0.32 (-2.27%) Market Cap: 281.86 Mil Enterprise Value: 148.05 Mil PE Ratio: 0 PB Ratio: 2.19 GF Score: 18/100

Q1 2025 Zelluna ASA Earnings Call Transcript

May 8, 2025 / 07:00 AM GMT

Release Date Price: kr14 (-4.76%)

Transcript

Key Points

Positve

Zelluna ASA (FRA:7UM0) became the first cell therapy company listed on the Oslo Stock Exchange, marking a significant milestone.
The company successfully developed, scaled, and automated its proprietary manufacturing process for TCRNK therapies, de-risking its path to clinical trials.
Zelluna ASA's manufacturing process can produce hundreds of doses from a single batch, addressing a key limitation of current cell therapies.
The company has a strong IP position, potentially allowing it to dominate the therapeutic space if its platform demonstrates efficacy.
Zelluna ASA is advancing its lead asset, ZIMA41, towards clinical trials, with plans to generate initial clinical data in 2026, which could be a significant value inflection point.

Negative

The company faces challenges in treating solid tumors, which remain difficult to address despite advancements in cell therapies.
Zelluna ASA's financial runway is expected to last only until the second quarter of 2026, indicating potential funding challenges.
The company experienced higher payroll expenses due to an increased number of employees following a business combination.
There were significant transaction costs related to the business combination, impacting financial results.
The cash burn level is expected to remain high until operational synergies are realized, which may affect financial stability.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZLNA.OL - Zelluna ASA
Q1 2025 Zelluna ASA Earnings Call
May 08, 2025 / 07:00AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning.

My name is Namir Hassan, the CEO of Zaluna, and I'm delighted to present to you today our first quarter business update and financial results.

Can I have the next slide, please?

This is our disclaimer slide.

Next slide, please. So the contents of the presentation today is we'll highlight the key events over the first quarter.

We will go through the Zallua TCRNK technology and pipeline, provide a financial update, and then summarize at the end.

Can I have the next slide, please?

And the next slide, please.

So, I wanted to start with this, a symbolic and momentous occasion for the company.

Zaluna being the first ever cell therapy company to be listed on

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.